E-Mail
IMAGE: Zhenyu Yue, PhD, Professor of Neurology and Neuroscience, Director of Basic and Translational Research of Movement Disorders, Icahn School of Medicine at Mount Sinai and senior author of the paper. view more
Credit: Mount Sinai Health System
Mount Sinai Researchers Find Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell Growth through activating protein kinase A (PKA) (Patent pending)
Corresponding Author: Zhenyu Yue, PhD, Professor of Neurology, Aidekman Family Professorship, Director of Basic and Translational Research in Movement Disorders, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai.
Bottom Line: We uncovered a mechanism that tumor cells exploit selective autophagy for metabolic reprogramming that benefits tumor cell growth and offers resistance to glucose deprivation. Our study suggests that AKAP220-mediated autophagy as a novel therapeutic target for specific cancer treatment
Researchers reveal novel therapeutic target in the treatment of certain cancers
Mount Sinai Researchers Find Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell Growth through activating protein kinase A (PKA) (Patent pending)
Corresponding Author: Zhenyu Yue, PhD, Professor of Neurology, Aidekman Family Professorship, Director of Basic and Translational Research in Movement Disorders, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai.
Bottom Line: We uncovered a mechanism that tumor cells exploit selective autophagy for metabolic reprogramming that benefits tumor cell growth and offers resistance to glucose deprivation. Our study suggests that AKAP220-mediated autophagy as a novel therapeutic target for specific cancer treatment.